A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.
A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'-deoxythymidine (AZT) and to (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.
Smith
R A
RA
Eccles Institute of Human Genetics, University of Utah, Salt Lake City, Utah 84112, USA.
Klarmann
G J
GJ
Stray
K M
KM
von Schwedler
U K
UK
Schinazi
R F
RF
Preston
B D
BD
North
T W
TW
D019380:Anti-HIV Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000302:isolation & purification; D015497:HIV-1 / Q000235:genetics / Q000472:pathogenicity; D006367:HeLa Cells; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D017354:Point Mutation; D011392:Proline / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D012694:Serine / Q000235:genetics
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D012694:Serine; D011392:Proline; D054303:HIV Reverse Transcriptase